Conferences - Results from #8820

Viewing 8821-8840 of 11724 articles

ESMO 2017: Cabozantinib for the treatment of patients with metastatic variant histology renal cell carcinoma: A retrospective study

ESMO 2017: Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)

ESMO 2017: Medical Costs and Health Care Resource Use in Elderly US Patients With Newly Diagnosed Metastatic or Surgically Unresectable Urothelial Carcinoma Using Surveillance, Epidemiology, and End Results (SEER) Medicare Data

ESMO 2017: Real World Treatment Costs and Resource Utilization among Patients with Metastatic Bladder Cancer

ESMO 2017: The prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic germ cell tumors

ESMO 2017: Management of M0 Patient with Rising PSA: How can PET imaging help?

ESMO 2017: The M0 Patient with Rising PSA - Case Presentation: The clinical problem, a multi-disciplinary issue

ESMO 2017: A Phase II Clinical Trial of Radium-223 Activity in Patients with mCRPC with Asymptomatic Progression While on Abiraterone Acetate or Enzalutamide Besides AR-V7 Mutational Status (EXCAAPE)

ESMO 2017: Immune Checkpoint Inhibitors in Prostate Cancer

ESMO 2017: Comparison of tumor mutational burden in relevant molecular subsets of metastatic urothelial cancer

ESMO 2017: Therapeutic Vaccines in Prostate Cancer

ESMO 2017: Adjuvant sunitinib in patients with high risk renal cell carcinoma (RCC): Safety and therapy management in S-TRAC trial

ESMO 2017: Immunogenomics of Lethal Prostate Cancer

ESMO 2017: Basic immunobiology in Prostate Cancer

ESMO 2017: A Change of Paradigm in First-Line Treatment of Metastatic Renal Cell Carcinoma?

ESMO 2017: IMmotion150: Novel Radiological Endpoints and Updated Data From a Randomized Phase II Trial Investigating Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma

ESMO 2017: Patient preference between Cabazitaxel and Docetaxel for first-line chemotherapy in metastatic castration-resistant prostate cancer: results from the CABADOC randomized trial

ESMO 2017: Progression-free survival by independent review and updated overall survival results from Alliance A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma

ESMO 2017: Adding abiraterone for patients with high-risk prostate cancer (PCa) starting long-term ADT: Outcomes in non-metastatic (M0) patients from STAMPEDE

ESMO 2017: What are the optimal systemic treatments for men with metastatic, hormone-sensitive prostate cancer? A STOPCaP systematic review and network meta-analysis

437
438
439
440
441
442
443
444
445
446